SAN FRANCISCO, June 29, 2026 /PRNewswire/ -- Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca ...
ERAS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Erasca, Inc. Securities Lawsuit - Contact Levi & Korsinsky Notice to Pension Funds, Asset Managers, and Fiduciaries ...
1d
Erasca, Inc. Deadline: ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"), ...
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Erasca, Inc (“Erasca” or the “Company”) (NASDAQ: ERAS) and reminds investors of the August 10, ...
(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Erasca, Inc. (NASDAQ: ERAS). Shareholders who purchased ...
SAN FRANCISCO, July 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused ...
Critical Information: ERAS Investors Lost $11.59 Per Share as Artificially Inflated Stock Price Collapsed Following Dual Corrective Disclosures on April 27-28, 2026 NEW YORK, July 8, 2026 /PRNewswire/ ...
(MENAFN- GlobeNewsWire - Nasdaq) Erasca's SEC Filings Allegedly Failed to Warn Investors That ERAS-0015's Competitive Comparisons Were Scientifically Unsupported and Legally Vulnerable, Contributing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results